$SDZ (-0,76 %) - Approval for Enzeevu
The generics manufacturer has received approval in the USA for the biosimilar Enzeevu. Enzeevu is an active ingredient for the treatment of neovascular age-related macular degeneration, which Sandoz hopes will lead to growth in the important US market. The copycat drug Enzeevu is based on the blockbuster Eylea from Regeneron.
GG
$SDZ (-0,76 %) - Convincing quarterly figures from Sandoz
The generics manufacturer generated sales of $2.6 billion in the second quarter of 2024, which corresponds to an increase of 9% in constant currencies. In the first half of 2024, sales rose by 7% to $5.0 billion. The biosimilar business in particular grew by 29%. Based on the positive business performance, Sandoz has raised its full-year sales growth guidance to a mid to high single-digit range in constant currencies.
Own position:
38 shares at 27.60
Happy Investing
GG
